N-linked glycosylation requires the synthesis of an evolutionarily conserved lipid-linked oligosaccharide (LLO) precursor that is essential for glycoprotein folding and stability. Despite intense research, several of the enzymes required for LLO synthesis have not yet been identified. Here we show that two poorly characterized yeast proteins known to be required for the synthesis of the LLO precursor, GlcNAc 2 -PP-dolichol, interact to form an unusual hetero-oligomeric UDP-GlcNAc transferase. Alg13 contains a predicted catalytic domain, but lacks any membrane-spanning domains. Alg14 spans the membrane but lacks any sequences predicted to play a direct role in sugar catalysis. We show that Alg14 functions as a membrane anchor that recruits Alg13 to the cytosolic face of the ER, where catalysis of GlcNAc 2 -PP-dol occurs. Alg13 and Alg14 physically interact and under normal conditions, are associated with the ER membrane. Overexpression of Alg13 leads to its cytosolic partitioning, as does reduction of Alg14 levels. Concomitant Alg14 overproduction suppresses this cytosolic partitioning of Alg13, demonstrating that Alg14 is both necessary and sufficient for the ER localization of Alg13. Further evidence for the functional relevance of this interaction comes from our demonstration that the human ALG13 and ALG14 orthologues fail to pair with their yeast partners, but when co-expressed in yeast can functionally complement the loss of either ALG13 or ALG14. These results demonstrate that this novel UDP-GlcNAc transferase is a unique eukaryotic ER glycosyltransferase that is comprised of at least two functional polypeptides, one that functions in catalysis and the other as a membrane anchor.
Man 5 GlcNAc 2 -PP-dol by enzymes that have their catalytic domain on the cytosolic side of the ER membrane and use sugar nucleotide substrates (2, 5, 6) . The enzymes that catalyze addition of the next seven sugars (four mannoses and three glucoses) do so within the lumen of the ER and use dolichol-linked sugar substrates (see Ref. 1 for review). Once assembled, this core oligosaccharide is transferred to protein by oligosaccharyltransferase through an N-glycosidic bond to an asparagine that is part of the Asn-X-(Ser/Thr) consensus sequence (7) . Proteinlinked oligosaccharide is immediately modified by the removal of glucoses and mannose by ER glucosidases and mannosidases. Failure to properly synthesize, transfer, or modify the N-linked glycan results in glycoproteins that are recognized by the quality control systems that restrict these aberrant proteins from exiting the ER to the Golgi and target their degradation (for review see Refs. 8 and 9).
In the yeast, Saccharomyces cerevisiae, many of the glycosyltransferases that catalyze synthesis of the core oligosaccharide have been identified. All of the ALG genes (asparagine-linked glycosylation) identified thus far (ALG1-12) encode membrane-spanning glycosyltransferases that have their catalytic domains on one or the other side of the ER membrane, consistent with the topological constraints of this pathway (10 -20) . In all organisms studied thus far, ALG mutations affecting the cytosolic reactions leading to Man 5 GlcNAc 2 -PP-dol synthesis result in lethality or very severe phenotypes (19, 21, 22) . Mutations affecting the later, luminal intermediates of LLO synthesis manifest as a range of phenotypes, from undetectable in S. cerevisiae (12, 13, 15, 16, 18, 22, 23) to the heterogenous phenotypes associated with congenital disorders of glycosylation (CDG) in humans (24, 25) . All of the ALG genes are highly conserved among eukaryotes, although certain unicellular eukaryotes are missing a subset (26) . These unicellular organisms consequently produce lipid-linked oligosaccharides that are shorter than Glu 3 Man 9 GlcNAc 2 PP-dol that is produced in S. cerevisiae and in humans. With the exception of Giardia lamblia and Plasmodium falciparum, which produce LLO lacking mannose and glucose, the shortest glycan produced by all eukaryotes that have been examined is Man 5 GlcNAc 2 -PP-dol (26) . The evolutionary conservation and essentiality of the proteins synthesizing Man 5 GlcNAc 2 -PP-dol underscore the importance of this glycan and the reactions that occur on the cytosolic face of the ER that lead to its assembly.
Despite its importance, the identity of several of the enzymes that catalyze the reactions on the cytosolic face of the ER remains a mystery. Using a bioinformatics approach, two S. cerevisiae ORFs (YGL047w and YBR070c) were recently identified that are distantly related to the bacterial MurG UDP-GlcNAc glycosyltransferase involved in peptidogly-can synthesis and that are implicated in playing a role in N-linked glycosylation (27) . Attenuated expression of either of these genes affects the second step of lipid-linked oligosaccharide synthesis, the addition of a ␤1,4-linked GlcNAc to GlcNAc-PP-dol that produces GlcNAc 2 -PPdol on the cytosolic face of the ER (27) . Remarkably, unlike any other eukaryotic ER glycosyltransferases, Ygl047w, which we designate here as Alg13, is predicted to contain a consensus glycosyltransferase catalytic domain but lacks any predicted membrane-spanning domains. The other polypeptide, Ybr070c, which we designate as Alg14, contains several predicted membrane-spanning domains but lacks any sequences that are predicted to participate in sugar transfer. Because Alg13 contains a domain that is strongly related to the catalytic domain found in other UDP-sugar transferases and displays a mutant phenotype that demonstrates its involvement in LLO synthesis, it seems likely to play a direct role in UDP-GlcNAc transfer. The role of Alg14 is less clear, particularly because "split" glycosyltransferases are unprecedented among eukaryotes. In this work we have tested the hypothesis that Alg13 and Alg14 interact on the ER face to form a functional heterooligomeric UDP-GlcNAc glycosyltransferase whose membrane-spanning domain and catalytic domain are on separate polypeptides. We demonstrate that these enzymes physically interact with one another on the ER membranes, and that Alg14 is required to recruit Alg13 from the cytosol to the ER. Furthermore although neither of the human Alg13 and Alg14 orthologues can interact with their yeast partners, when coexpressed these proteins can functionally complement the loss of ALG13 or ALG14. We speculate that this enzyme has evaded identification because it is an unusual hetero-oligomeric glycosyltransferase, comprised of at least two distinct polypeptides, both of which are required for LLO biosynthesis.
EXPERIMENTAL PROCEDURES
Yeast Strains and Media-Yeast strains used in this study are listed in TABLE ONE. W303a (MATa ade2-1 ura3-1 his3-11 trp1-1 leu2-3,112 can1-100) is the parental strain for all the strains used in work. Epitope tagging and replacement of promoters or chromosomal loci employed PCR-mediated recombination (28) using the standard pFA6a-series of plasmids as template (29) . The pFA6a-3FLAG-His3MX6, a derivative of pFA6a-3HA-His3MX6 was kindly provided by M. Umemura. Standard yeast media, growth conditions, and genetic techniques were used (30) .
In XGY151 and XGY154, the ALG14 and ALG13 chromosomal promoter sequences including the initiating ATG (220 and 202 base pairs upstream the initiating ATG, respectively) were replaced by the GAL1 promoter followed by a start codon and the triple HA epitope marked with the Schizosaccharomyces pombe his5 ϩ gene. XGY154 also contain an additional copy of the RPT6 gene and its upstream promoter sequence integrated at the trp1 locus. RPT6 is an essential gene that lies adjacent to ALG13 but that is transcribed from the opposite strand of chromosome VII. We found that replacement of the ALG13 promoter with the GAL1 promoter interferes with normal RPT6 expression. Therefore a DNA fragment, containing the RPT6 ORF and 267 bp of 5Ј-flanking sequence, was cloned into the TRP1 integration vector, pRS304 (31), linearized, and integrated at the trp1 locus in XGY154. SKY202 was created by replacing the ALG13 allele with a C-terminal HA-tagged ALG13 allele, marked with the S. pombe his5 ϩ gene. The XGY155 strain contains a replacement of the chromosomal ALG13 locus with a C-terminal triple FLAG-tagged ALG13 allele, marked by the S. pombe his5 ϩ gene. XGY156 was generated from XGY155 by replacing 220 base pairs upstream of the ALG14 chromosomal locus with the GAL1 promoter followed by the triple HA epitope, marked with the TRP1 gene. XGY158 was constructed from XGY156 and contains a 3HA-tagged ALG14 allele under its own promoter integrated at ura3 (by integration of pXG202 (see "Plasmid Construction" below) and in addition contains a 3HA-tagged ALG14 allele driven by the glucose repressible GAL1 promoter. XGY166 contains a normal ADE2 allele integrated at the ade2 locus, and the pTiKmRFP plasmid at ura3 locus. pTiKmRFP expresses Kar2-mRFP-HDEL (see "Plasmid Construction", below). This strain allowed the fluorescent analysis of the Kar2-mRFP-HDEL ER marker using monomeric RFP, without interference of the red pigment that accumulates due to the ade2 mutation. Strains XGY167A and 168 were derived from XGY166 and contain a replacement of the chromosomal ALG13 and ALG14 loci, respectively, with GFP-tagged alleles that are marked with the S. pombe his5 ϩ gene.
Plasmid Constructions-Standard molecular biology techniques were used for all plasmid constructions. The correct sequence of all PCR-amplified products was verified by DNA sequencing. The sequences of primers used in this study are available upon request. To express plasmid borne genes from the ALG13 promoter, the promoter sequence of the ALG13 gene was amplified directly from the yeast genome by PCR, digested with XhoI and EcoRI and cloned into the URA3, integrative plasmid, pRS306 (31) , to generate pXG200. The same strategy was used to create pXG201, which contains the ALG14 promoter. This PCR product was cloned into the KpnI/HindIII sites of pRS306. To express the 3HA-ALG14 gene from the ALG14 promoter, the 3HA-ALG14 gene was amplified from strain XGY151 and cloned into the HindIII/SmaI sites of pXG201 to create pXG202. Linearization Human ALG13 (GLT28D1) and ALG14 (MGC19780) cDNAs were amplified by PCR using Marathon-Ready TM cDNA derived from human whole brain (Clontech, Palo Alto, CA). The amplified fragments were digested with HinDIII and XbaI and inserted into expression vector, pFLAG-CMV4 (Sigma) to generate pXG203 (containing FLAGhALG13) and pXG204 (containing FLAG-hALG14). To express the human ALG13-FLAG-tagged gene from the yeast ALG13 promoter, pXG203 was used as template for PCR to amplify ALG13 with a primer set encoding the FLAG peptide sequence. The product was digested with EcoRI and EcoRV, and cloned into EcoRI/SmaI sites of pXG200. This generated pXG205, a URA3 integration plasmid that expresses FLAG-tagged human ALG13 from the yeast ALG13 promoter. An XhoI/XbaI fragment including the ALG13 promoter and entire hALG13-FLAG fusion gene from pXG205 was cloned into the SalI/XbaI sites of the LEU2, integrative plasmid, pRS305, to create a similar plasmid, pXG206, but marked with LEU2. Linearization of this plasmid with EcoRV, within the LEU2 gene, targets integration at the leu2 locus. To express the human ALG14 homologue from the GAP1 promoter, pXG204 was used as a template to amplify the ALG14-FLAG ORF, with primers tailed with sequences encoding the FLAG tag. The product was digested with SacI and EcoRV, and cloned into SacI/SmaI sites of pTiSac (32) to generate pXG207. To create pRS304RPT6, the RPT6 gene including its promoter sequence was amplified by PCR, digested with XhoI and EcoRV, and cloned into XhoI/SmaI sites of the TRP1, integrative plasmid pRS304.
Subcellular Fractionation and Western Immunoblotting AnalysisYeast were grown and harvested at logarithmic growth phase (A 600 1-3). About 2 ϫ 10 9 cells were incubated in 1 ml of A-Buffer (100 mM EDTA, 0.5% ␤-mercaptoethanol, 10 mM Tris-HCl, pH 7.5) for 15 min at 30°C, spun down, and then resuspended in 0.8 ml of S-Buffer (1.0 M sorbitol, 2 mM MgCl 2 , 0.14% ␤-mercaptoethanol, 50 mM Tris-HCl, pH 7.5) with 50 units/A 600 zymolyase 100T (SEIKAGAKU Co.). After incubating at 30°C for 45ϳ60 min, during which time 70% of cells were converted to spheroplasts, cells were collected and washed twice with ice-cold S-Buffer. The cells were suspended in 1 ml of lysis buffer (0.2 M sorbitol, 1 mM EDTA, 50 mM Tris-HCl, pH 7.5) containing protease inhibitors and lysed by Dounce homogenization, with 20 strokes of a Teflon pestle on ice. Unbroken cells and debris were pelleted by centrifugation at 1000 ϫ g for 10 min to yield a crude extract. The post 1000 ϫ g supernatant was collected and centrifuged at 13,000 ϫ g for 15 min, which yielded the P13 pellet and the S13 supernatant. The S13 fraction was centrifuged at 100,000 ϫ g for 60 min to yield the P100 and S100 supernatant. Together with crude extract and S100 fraction, P13 and P100 fraction were resuspended in a suitable mount of lysis buffer and protein concentrations were determined by BCA protein assay (Pierce). 10 g of each fraction were separated by 10% SDS-PAGE and transferred to Immobilon-PVDF membranes (Millipore).
To make the membrane fraction that was used in A and B of Fig. 4 , exponentially growing yeast cells (10 A 600 ) were homogenized by vortexing with glass beads in ice-cold lysis buffer and centrifuged at 3000 ϫ g for 10 min to remove unbroken cells and wall debris. The 3000 ϫ g supernatant was directly centrifuged at 100,000 ϫ g for 30 min in a Beckman Optima TL ultracentrifuge. The soluble protein-containing supernatant (S100) was precipitated with 10% trichloroacetic acid and resuspended in 100 l of lysis buffer. The membrane-containing pellet (P100) was resuspended in 100 l of lysis buffer. Equal volumes were separated by 10% SDS-PAGE and transferred to Immobilon-PVDF membranes (Millipore). To make the cellular extracts used in Fig. 7 , exponentially growing yeast cells were homogenized by vortexing with glass beads in ice-cold lysis buffer and centrifuged at 3000 ϫ g for 10 min to remove unbroken cells and wall debris. The supernatants were collected and used directly for 8% SDS-PAGE to analyze the electrophoretic mobility of carboxypeptidase Y (CPY).
The Alg13-FLAG protein was detected by a mouse anti-FLAG monoclonal antibody conjugated to alkaline phosphatase (anti-FLAG M2-AP, Sigma) and detected directly by chemiluminescence (CDP-Star Detection Reagent, Amersham Biosciences). Mouse monoclonal anti-Dpm1 and anti-CPY (Molecular Probes) were used to detect Dpm1p and CPY. Anp1p was detected with rabbit polyclonal anti-Anp1 antibody (from Sean Munro). HA-Alg14p, Alg13-HA were detected using 12CA5 monoclonal anti-HA antibody. Primary antibody staining was followed by incubation with a secondary anti-rabbit or anti-mouse antibody conjugated to horseradish peroxidase (Amersham Biosciences) followed by chemiluminescence (ECL, Amersham Biosciences).
Co-immunoprecipitation-Exponentially growing yeast cells were harvested at an A 600 of 1-3 and converted to spheroplasts with lyticase. To prepare detergent extracts, spheroplasts from 5-6 Absorbance units of cells were resuspended in 500 l of ice-cold lysis buffer (150 mM NaCl, 10 mM HEPES-KOH, pH 7.5, 5 mM MgCl 2 ) that contained protease inhibitors and 1% digitonin as described (33) . Epitope-tagged proteins in digitonin extracts were immunoprecipitated with Anti-HA affinity matrix (Roche Applied Science Co.) or Anti-FLAG M2 affinity gel (Sigma). After fractionation by SDS-PAGE, immunoprecipitates were transferred to Immobilon-PVDF membranes. To detect the FLAG-tagged proteins, the membrane was incubated with a mouse anti-FLAG monoclonal antibody conjugated to alkaline phosphatase (ANTI-FLAG M2-AP). To detect the HA-tagged protein, the membrane was incubated with a rabbit anti-HA polyclonal antibody (HAprobe Y-11, Santa Cruz Biotechnology) followed by a secondary antirabbit antibody conjugated to horseradish peroxidase (Cell Signaling Technologies).
Analysis of GFP and mRFP Fusion Proteins-To visualize the localization of GFP and mRFP fusion proteins, cells were grown to an A 600 of 1-3 in YPAD. After washing the cells with phosphate-buffered saline ϩ 2% glucose, GFP fluorescence was imaged using the NIBA filter (Olympus), and mRFP fluorescence was imaged using the WIG filter (Olympus) on an Olympus BX50 microscope.
RESULTS

Alg13 and Alg14
Physically Interact-Although a role for Alg13 as a glycosyltransferase involved in GlcNAc 2 -PP-dol synthesis requires its association with the ER membrane, it lacks any membrane-spanning domains. Interestingly, ALG14 encodes an uncharacterized membrane protein that when underproduced, leads to phenotypes similar to that of alg13 (27) . These data suggest a model in which these proteins pair with one another on the cytosolic face of the ER to form a functional heterooligomeric UDP-GlcNAc transferase that catalyzes the second step of core oligosaccharide synthesis on the ER.
Thus, Alg13 and Alg14 should physically interact. To test this idea, we performed a co-immunoprecipitation assay. Yeast strains were constructed that co-express C-terminally FLAG-tagged Alg13 and N-terminally HA-tagged Alg14 (strain XGY158). This strain also contains an ALG14 allele driven by the GAL1-promoter but this allele is repressed when this strain is grown on glucose. Both of these tagged alleles are functional, expressed at physiological levels when grown on glucose, and complemented both the glycosylation defect and growth phenotype of the alg13 and alg14 mutants, respectively (data not shown). Digitonin-containing protein extracts were prepared from these strains and clarified by centrifugation at 100,000 ϫ g to remove any nonspecific protein aggregation (see "Experimental Procedures"). Alg14 was immunoprecipitated with anti-HA antibodies, the immunoprecipitates were separated by SDS-PAGE, and blotted with anti-FLAG antibodies to determine if Alg13 precipitated with Alg14. By this assay, we found that Alg13 co-precipitated with Alg14 with high affinity and specificity (Fig.  1) . Co-precipitation of Alg13 with Alg14 depended on the co-expression of Alg14-HA (Fig. 1, lane 6 ) and was independent of the antibodies used; immunoprecipitation of Alg13-FLAG with anti-FLAG antibodies also resulted in the co-precipitation of Alg14-HA with Alg13-FLAG (Fig. 1, lane 7) . In addition, we found no evidence for the co-precipitation of other membrane proteins (e.g. Wbp1 (Fig. 1, lane 8 and data not shown), suggesting that this is a specific interaction. Taken together, these results demonstrate that these proteins physically interact.
Alg13 and Alg14 Are Localized at the ER-Both Alg13 and Alg14 should be localized on ER membranes if they pair to form the UDPGlcNAc transferase that catalyzes the formation of GlcNAc 2 -PP-dol on the cytosolic face of the ER. To test this idea, we constructed strains that produce GFP-tagged Alg13 and Alg14 at physiological levels to examine their localization in live cells (strains XGY167A and XGY168; see "Experimental Procedures"). As judged by fluorescence microscopy, both of these proteins, at least in part, localized in a perinuclear pattern that is characteristic of the yeast ER (Fig. 2) . The identity of this organelle was confirmed by the co-localization with an ER reporter protein, Kar2-mRFP-HDEL (Fig. 2, A and B) , which contains the Kar2 signal sequence fused to mRFP bearing a C-terminal HDEL ER retention signal (strain XGY166; see "Experimental Procedures"). While Alg14-GFP was detected primarily in ER membranes by this assay (Fig. 2A) , the fluorescence observed in cells expressing ALG13-GFP was more diffuse and more difficult to detect. Nonetheless, a significant proportion of ALG13-GFP co-localized with mRFP-Kar2-HDEL (Fig. 2B) , demonstrating that both Alg13 and Alg14 are associated with the ER.
Whereas the analysis of the GFP-tagged Alg13 provided strong evidence for its ER localization, the more diffuse weak GFP-staining pattern suggested that Alg13, which lacks any predicted hydrophobic domains, might also localize in the cytoplasm. To determine if this was the case, the sedimentation properties of Alg13 was analyzed by subcellular fractionation. Yeast strains were constructed that co-express an FIGURE 1. The Alg14 and Alg13 proteins co-immunoprecipitate. Yeast cells XGY158, XGY155, and W303a strains were grown to mid-log phase, and 1.0% digitonin detergent extracts were prepared as described under "Experimental Procedures," clarified by centrifugation at 100,000 ϫ g, and quantitatively analyzed for the presence of Alg13-FLAG by immunoblotting with anti-FLAG antibody (lanes 1-3) or immunoprecipitated with anti-HA affinity matrix (lanes 4, 5, and 6) or anti-FLAG antibodies (lanes 7 and  8) . Extracts or immunoprecipitated proteins were separated by 10ϳ20% gradient SDS-PAGE, immunoblotted with rabbit anti-FLAG antibody for the detection of Alg13-FLAG (lanes 1-6) , anti-HA for the detection of Alg14-HA (lane 7), or anti-Wbp1 antibody for the presence of Wbp1 (lane 8), and detected by chemiluminescence. HA-tagged allele of ALG14 and a FLAG-tagged allele of ALG14 (XGY158) that produced proteins at comparable levels (Fig. 3A) . Lysates from these cells were subjected to differential centrifugation to separate ER from soluble, cytosolic proteins (see "Experimental Procedures"). Lysates were centrifuged at 13,000 ϫ g to sediment ER membranes. The resulting S13 supernatant was further centrifuged at 100,000 ϫ g to separate lighter membrane components (P100), including the Golgi and small transport vesicles, away from soluble cytosolic proteins that remain in the supernatant (S100). Equivalent amounts of protein from each of these fractions, i.e. the P13, P100, and S100, were separated by SDS-PAGE and immunoblotted with anti-HA and anti-FLAG antibodies to detect Alg13 and Alg14 (Fig. 3B ). In agreement with the immunofluorescence analysis of GFP-tagged proteins, described above, we observed that the majority Alg14-HA fractionated with the ER, co-sedimenting with the ER protein, Dpm1, and away from Anp1, a Golgi marker (Fig. 3B) . Alg13-FLAG also primarily associated with ER membranes, but was also found in the S100 fraction (Fig. 3B) . The amount of Alg13 associated with membranes varied from experiment to experiment, but was always at least a 5-10-fold enriched in the ERenriched P13 fraction compared with the S100. Taken together, these results demonstrate that the majority of both Alg14 and Alg13 are associated with the ER membrane.
Alg14 Is Necessary and Sufficient to Recruit Alg13 to the ER-Despite the absence of any predicted membrane-spanning regions, our fractionation results show that at physiological levels Alg13 is predominantly associated with ER membranes. However, a different pattern of localization was observed in a strain overexpressing ALG13-FLAG under the TPI1 or GAL1 promoter (Fig. 4 and data not shown) . A substantial A, overexpression of Alg13 results in its cytosolic and ER localization. Extracts from yeast expressing ALG13-HA (SKY202) or GAL1pr-ALG13-HA (XGY154) grown on medium supplemented with galactose were fractionated to separate membrane and soluble proteins. Equivalent amounts of each fraction were separated by 10% SDS-PAGE (see "Experimental Procedures"), and the amount of Alg13-HA in each fraction was compared after immunoblotting with anti-HA antibody. B, depletion of Alg14 results in the cytosolic partitioning of Alg13. Yeast containing a glucose-repressible/galactose-inducible GAL1pr-HA-ALG14 allele and in addition, a FLAG-tagged ALG13 allele (SKY203) were grown in galactose-containing medium, and at time 0, shifted to glucose-containing medium. At variable times, aliquots of cells were collected, lysed by vortexing with glass beads, and fractionated to separate membrane from soluble proteins, as described under "Experimental Procedures." Equivalent amounts of proteins from these fractions were separated by SDS-PAGE and blotted with anti-FLAG antibodies to detect Alg13-FLAG, as described under "Experimental Procedures." C, overexpression of Alg14 suppresses the cytosolic partitioning of Alg13. Yeast cells expressing ALG13-FLAG and both a native and GAL1 promoter-driven ALG14 allele (XGY158) were grown to mid-log phase in medium supplemented with either glucose (left panel) or galactose (right panel). Extracts were fractionated to separate ER (P13) from soluble proteins (S100). 10 g of protein from each fraction were separated by SDS-PAGE, immunoblotted, and Alg13-FLAG was detected with anti-FLAG antibody. FIGURE 3. Alg13 and Alg14 associate with ER membranes. Extracts were prepared from the parental isogenic strain, W303a, as a negative control or a strain co-expressing HA-tagged-ALG14 gene and FLAG-tagged ALG13 under their native promoters (XGY158), by growth in a glucose medium. These extracts were analyzed by immunoblotting with anti-HA or anti-FLAG antibody after separation on 10% SDS-PAGE (A) or after subcellular fractionation (B) as described under "Experimental Procedures," in which 10 g of proteins from each fraction were separated by SDS-PAGE and analyzed by immunoblotting with antibodies against Alg14-HA, Alg13-FLAG, Dpm1 (an ER marker), or Anp1 (a Golgi marker).
portion of Alg13-FLAG remained soluble and was found in the S100 fraction whereas similar amounts of Alg13-FLAG co-sedimented in the membrane-containing fraction (Fig. 4A, compare lanes 2 and 4) . This result demonstrates that overproduction of Alg13 can shift its localization so that more of it partitions in the cytoplasm. Based on our demonstration of the physical interaction between Alg13 and Alg14 (Fig. 1) , one explanation for this result is that the localization of Alg13 to the ER is dependent upon its stoichiometric association with Alg14, that when saturated with excess Alg13 leads to its increased cytosolic localization. If Alg14 is required for the recruitment of Alg13 to the ER, depletion of Alg14 from the ER should result in the re-localization of Alg13 to the cytosol. To test this idea, we analyzed the localization of Alg13 as a function of Alg14 depletion over time. A strain was constructed containing ALG14 under the control of the glucose-repressible GAL1p-promoter and in addition, a FLAG-tagged allele of ALG13, driven by its native promoter (SKY203). These cells were grown under non-repressing conditions and at time zero, glucose was added to repress ALG14 expression. Aliquots of cells were removed every 4 h, and lysates prepared from these cells were subjected to differential centrifugation. Membrane and soluble fractions were analyzed by SDS-PAGE and immunoblotted with anti-FLAG antibodies to analyze the sedimentation properties of Alg13 (Fig. 4B) . In this strain, which overproduces Alg14, at time zero, Alg13 was found predominantly in the membrane fraction (Fig. 4B, compare lanes 1 and 2) . However, concomitant with a loss of ALG14 (not shown), the proportion of Alg13 that fractionated in the cytosolic fraction increased. By 24 h, when cells could no longer divide because of the depletion of Alg14 (data not shown), equivalent amounts of Alg13 were found in both the membrane and cytosolic fractions (Fig. 4B, lanes 7 and 8) . Depletion of Alg14 results in the cytosolic partitioning of Alg13, therefore, the ER localization of Alg13 is dependent on Alg14.
We further asked if Alg14 is also sufficient to recruit Alg13 to the ER. To address this question, we examined if a concomitant increase in ALG14 expression can rescue the Alg13 cytosolic localization. We analyzed the localization of Alg13 in a yeast strain containing both its normal ALG14 gene and a GAL1 promoter-driven ALG14 allele that is overexpressed in the presence of galactose. This strain (XGY158) also contained FLAG-tagged ALG13. This strain thus expresses normal levels of ALG14 when grown on glucose, but overexpresses ALG14 when grown in galactose. The affect of ALG14 overexpression on Alg13 localization was assayed by preparing lysates from cells grown in galactose or glucose, separating the membrane and soluble proteins by a differential centrifugation, and assaying the amount of Alg13-FLAG in each fraction by immunoblotting (Fig. 4C) . When grown in glucose, when ALG14 is not overexpressed, Alg13 was observed in both the P13 ERenriched fraction and in the S100 soluble protein fraction, at about a 4:1 ratio. In marked contrast, overexpression of ALG14 by growth in galactose resulted in significant enrichment of Alg13-FLAG with the P13 fraction. Alg13 was almost undetectable in the S100 fraction under these conditions. This result is also consistent with our failure to OCTOBER 28, 2005 • VOLUME 280 • NUMBER 43 observe any soluble Alg13 in the SKY203 strain grown on galactose (Fig.  4B, lane 2) and demonstrate that overexpression of ALG14 can recruit Alg13-FLAG to the ER and suppress the cytosolic localization of Alg13-FLAG. Thus, Alg14 is both necessary and sufficient for the recruitment of Alg13 to the ER.
Alg13 and Alg14 Form a Functional ER UDP-GlcNAc Transferase
Complementation of alg13 and alg14 Phenotypes by Human Orthologues-Data base searches demonstrate that both Alg13 and Alg14 have been conserved among eukaryotes, as predicted for proteins that are involved in the early steps of LLO biosynthesis. The alignment and comparative hydropathy profile of the yeast and human orthologues are shown in Fig. 5 . The human and yeast Alg13 proteins display limited but significant sequence similarity along their lengths (28% identity and 47% similarity/E value 6e-12) and are of a similar size; the yeast protein is predicted to have a molecular mass of 22.6 kDa, whereas the human Alg13 protein is about 18.2 kDa (Fig. 5A) . The Alg14 orthologues are slightly more similar in their overall sequence (35% identity and 53% similarity/E value ϭ 2e-18). However, the sequence of the Alg14 orthologues has completely diverged in the first 32 amino acids of the N terminus (Fig. 5B) . This region encompasses the first of three predicted membrane-spanning domains in Alg14. These Alg14 proteins are also predicted to be rather small; the yeast Alg14 is about 27 kDa and the human Alg14 protein is 24.1 kDa.
We cloned the human ALG13 and ALG14 cDNAs (see "Experimental Procedures") and tested them for functional complementation of the corresponding yeast alg13 and alg14 yeast mutants. Each of these cDNAs was cloned into a yeast vector that places their expression under the control of the corresponding yeast ALG13 or ALG14 promoters (pXG205 and pXG206). These plasmids were expressed in GAL1p-ALG13 or GAL1p-ALG14 strains and grown on medium supplemented with either galactose, or glucose to repress expression of the endogenous yeast gene. By this assay, we found that neither of these human genes could complement the growth defect of the corresponding mutant (Fig. 6A) . This failure to complement may be because of the inability of each of the human proteins to pair properly with their yeast partner, due to sequence divergence. To test this idea, the human ALG13 and ALG14 genes were co-expressed in either the GAL1p-ALG13 or GAL1p-ALG14 strains and again tested for complementation of lethality in the presence of glucose. In agreement with our hypothesis, we found that when co-expressed, the human ALG13 and ALG14 genes restored growth on glucose-containing medium to wild-type levels.
We also tested whether co-expression of these genes complemented the glycosylation phenotype that resulted from the attenuated expression of either GAL1p-ALG13 or GAL1p-ALG14 in glucose-repressing conditions. We analyzed the electrophoretic mobility of CPY as a reporter for N-linked glycosylation defects in the ER. This protein normally acquires four N-linked glycans in the ER, but the failure to correctly assemble a normal LLO causes a reduction in the efficiency with which the oligosaccharide is transferred from the lipid to the protein.
Thus N-linked glycosylation defects in the ER results in a typical "ladder" pattern on SDS-PAGE of hypoglycosylated CPY forms that lack one, two, three, or four glycans (e.g. Fig. 7) . Cells containing the GAL1 promoter-driven yeast ALG13 or ALG14, containing plasmids carrying the human genes were grown in galactose, then shifted into galactoseor glucose-containing medium. After growth for 6 -8 h, the yeast were harvested and resuspended again into galactose-or glucose-containing medium. Lysates were prepared from cells having gone through three such passages, and immunoblotted with anti-CPY antibodies (Fig. 7) . Consistent with previous results of Chantret et al. (27) , reduced expression of either Alg13 (Fig. 7, lane 3) or Alg14 (Fig. 7, lane 7) resulted in hypoglycosylation of CPY. The more pronounced CPY hypoglycosylation defect seen in the GAL1-ALG13 strain, compared with GAL1-ALG14 is likely due to residual Alg14 protein remaining in cells even FIGURE 6 . Complementation of alg13 or alg14 requires co-expression of the human ALG13 and ALG14 orthologues. A, GAL1pr-driven ALG13 and ALG14 strains fail to grow on glucose plate. Isogenic wild-type (W303a) and GAL1p-driven ALG13 (XGY154), ALG14 (XGY151), and ALG1 (XGY31) strains were streaked on YPA plates supplemented with galactose (left panel) and glucose (right panel) and then grown for 2 days at 30°C. B, co-expression of human ALG13 and ALG14 complement the growth defect of GAL1pr-driven ALG13 or ALG14 strains on glucose-containing medium. Isogenic GAL1pr-driven ALG13 strains (XGY154) harboring plasmid-borne human ALG13 (pXG205) only or both human ALG13 and ALG14 (pXG205 and pXG207) were streaked on YPA ϩ glucose plates and incubated for 2 days at 30°C (left panel). Isogenic GAL1p-driven ALG14 strain (XGY151) harboring human ALG14 (pXG207) only or both human ALG13 and ALG14 (pXG207 and pXG206) were also grown on YPA ϩ glucose plates (right panel). The growth properties of all these strains were compared with the parental wild-type strain (W303a). FIGURE 7. Co-expression of human ALG13 and ALG14 genes rescues the alg13 or alg14 glycosylation defect. Yeast strains containing GAL1p-driven ALG13 (XGY154) or ALG14 (XGY151) harboring plasmids containing the human ALG13 or ALG14 genes (pXG205 and pXG207, respectively), were grown to mid-log phase in YPA medium supplemented with galactose, shifted into YPA supplemented with galactose, or with glucose to repress expression of the ALG13 and ALG14 genes, and grown for 6ϳ8 h at 30°C. After three repeated passages of growth on glucose or galactose, cells were harvested and crude protein extracts were prepared as described under "Experimental Procedures." Protein extracts (4 g) were separated by 10% SDS-PAGE and blotted with an anti-CPY monoclonal antibody. The positions of the mature and hypoglycosylated forms of CPY lacking 1, 2, 3, or 4 N-linked glycans are indicated (37) .
after three passages in glucose, because Alg14 is much more stable than Alg13 (data not shown). Co-expression of the human ALG13 and ALG14 genes in either the GAL-ALG13 or GAL-ALG14 strains resulted in a significant increase in the proportion of fully glycosylated CPY that accumulated in these strains when grown on glucose (Fig. 7, compare  lanes 2 and 3, and 6 and 7) although the glycosylation defect was not restored to normal levels. Taken together, these data demonstrate that the human Alg13 and Alg14 proteins cannot productively interact with their yeast partner, but can pair with one another to form a functional UDP-GlcNAc transferase in yeast.
DISCUSSION
Alg13 meets most of the criteria demanded of the key enzyme that catalyzes the second step of LLO oligosaccharide biosynthesis. It contains a consensus UDP-sugar binding site, is required for the synthesis of GlcNAc2-PP-dol (27) , displays a severe N-glycosylation defect when underproduced, and is conserved among other eukaryotes. However, its lack of a membrane-spanning domain raised the question of how it can be recruited to the cytosolic face of the ER where this reaction occurs. Our results demonstrate that the ER localization of Alg13 is mediated through its physical interaction with Alg14, an essential ER protein that acts as a membrane anchor. Our data suggest a novel topological arrangement for this glycosyltransferase that contains at least two subunits, including Alg13, which mediates sugar transfer, and Alg14, which acts as a membrane anchor. To our knowledge, this is the first example of such a bipartite eukaryotic glycosyltransferase.
We have shown that Alg13 and Alg14 interact by co-immunoprecipitations assays. Recently, a number of other ER glycosyltransferases, namely Alg1, Alg2 and Alg11, which catalyze several steps of LLO biosynthesis on the cytosolic face of the ER have been shown to interact as hetero-oligomeric complexes that are important for their glycosyltransferase activity (32) . We have not determined the stoichiometry of Alg13 and Alg14 within the hetero-oligomer nor have we ruled out the possibility that there may be additional interactions between Alg13 and Alg14with these or other ER proteins that may modify the activity of the UDP-GlcNAc transferase activity. However, our results demonstrate that Alg14 is both necessary and sufficient for the localization of Alg13 to the ER. The depletion of Alg14 results in loss of Alg13 ER localization, as does Alg13 overexpression. The suppression of this latter phenotype by overexpression of ALG14 provides strong genetic data that are consistent with Alg14 being the sole cohort responsible for Alg13 recruitment.
Further support for the physiological relevance of the Alg13/14 hetero-oligomer comes from our analysis of the ALG13 and ALG14 human orthologues. Surprisingly, we found that complementation of either the alg13 or alg14 mutant phenotype occurs only when both human genes are expressed together. One interpretation of these data is that the ability of these human proteins to properly pair with their yeast counterparts has been lost through evolution but that these human proteins can pair with one another to form a functional hetero-oligomeric UDPGlcNAc transferase.
The use of secondary structure algorithms and hydropathy analyses predicts that Alg14p contains three transmembrane domains. This suggests that one end of the protein faces the lumen, while the other faces the cytosol. Several observations suggest that the N terminus of Alg14 is within the lumen and the C terminus is in the cytosol. First the first and third hydrophilic domains of Alg14 are predicted to be very short (just four and eleven amino acid residues, respectively). Thus a topological arrangement in which the N terminus is within the lumen and the C terminus is in the cytosol would result in significantly longer Alg14 domains oriented toward the cytosol. This topology would favor a more stable interaction with Alg13 on the cytosolic face of the ER, where Alg13 must function to catalyze the formation of GlcNAc2-PP-Dol. Second, Alg13 is homologous to the C terminus of the MurG glycosyltransferase whereas Alg14 shows distant similarity to the N terminus. Third, preliminary data supporting this topology comes from our phenotypic analysis of a functional chimeric protein, consisting of Alg13 fused to the C terminus of Alg14, that can complement loss of either ALG13 or ALG14. 3 This result implies that sequences in the C-terminal domains of Alg14 participate in its stable interaction with Alg13. The function of the N-terminal membrane-spanning domain of Alg14 is not known, but one possibility is that this region of the protein not only to tethers Alg13 to the ER membrane but also participates in the requisite recognition of dolichol in the membrane. The inability of the human Alg13 and Alg14 proteins to interact with their yeast partners suggests that important residues in the cytosolic facing domains of Alg14 and/or within the Alg13 protein have diverged sufficiently to destabilize the interaction with their yeast partners. A more careful analysis of the diverged residues within these domains may provide information about amino acids that mediate the interaction between Alg13 and Alg14.
Interestingly, a number of unicellular eukaryotic organisms were recently identified that lack certain ER glycosyltransferases and thus produce truncated N-linked glycans, demonstrating a precise correlation between the existence of defined N-linked glycans and the ALG genes required for their synthesis (26) . For instance Giardia lamblia, a protozoan considered to be an "ancient eukaryote," is missing all previously identified Alg glycosyltransferases except Alg7 (the UDP-GlcNAc: dolichol phosphate N-acetylglucosamine-1-phosphate transferase that catalyzes formation of GlcNAc-PP-dol) and produces N-linked glycans that consist entirely of GlcNAc 2 -PP-dol (26) . Encephalitozoon cuniculi, a microsporidian eukaryotic parasite that lacks mitochondria, makes no dolichol-PP precursors and does not possess any of the previously identified ALG glycosyltransferase genes. Our model for the postulated dual role of both Alg13 and Alg14 in the second step of the N-linked glycosylation pathway predicts that Giardia should possess both ALG13 and ALG14 genes, and that Encephalitozoon should possess neither. Consistent with this idea, searches of the databases demonstrate the existence of highly related Giardia ALG13 (GenBank TM accession no. EAA42775) and ALG14 (GenBank TM accession no. EAA40038) homologues, but no such related genes in the Encephalitozoon genome.
Whereas there are numerous examples of eukaryotic glycosyltransferases that function as part of larger oligomeric complexes (e.g. see (34) , there are few, if any examples of bipartite eukaryotic glycosyltransferases. Thus Alg13, the soluble, catalytic half of the protein, and Alg14, the membrane anchor, together represent a novel example of a eukaryotic bipartite glycosyltransferase within this large family of enzymes. Given the homology of Alg13 and Alg14 to the bacterial MurG protein, which may represent an ancient fusion of these two proteins, it appears that eukaryotes have evolved two distinct proteins where there was once just one. This raises the question of how such a bipartite arrangement may benefit the eukaryotic cell. One possibility that we are currently investigating is that a cytosolic component of the N-linked glycosylation machinery, particularly one that lies early in the pathway such as Alg13, may serve as a sensor for the metabolic state of the cell. In agreement with this idea, we find that Alg13 is a short-lived protein and overexpression of ALG13 is not well tolerated by yeast. 4 The rate of LLO synthesis influences, and is influenced by a variety of parameters affect-ing normal growth and secretion, by largely unknown mechanisms. The first step of this pathway, the formation of GlcNAc-PP-dol has been described as the first committed step of LLO biosynthesis (35) , and there is good evidence that this precursor is strongly inhibited by the formation of GlcNAc 2 -PP-dol (36) . Thus the enzymes required for synthesis of GlcNAc 2 -PP-dol provide attractive targets for the regulation of the N-linked glycosylation pathway. Our characterization of ALG13 and ALG14 provides the framework to examine how the cell regulates the formation of these critical oligosaccharide precursors.
